Patents by Inventor Jennifer Marugg

Jennifer Marugg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-substituted benzene sulfonamides
    Publication number: 20120270902
    Abstract: The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R1, R2, R3, R4, and R3?, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula (I).
    Type: Application
    Filed: February 13, 2012
    Publication date: October 25, 2012
    Applicant: ELAN PHARMACEUTICALS, INC.
    Inventors: Martin Neitzel, Jennifer Marugg
  • N-substituted benzene sulfonamides
    Patent number: 8193389
    Abstract: The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R1, R2, R3, R4, and R3?, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula (I).
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: June 5, 2012
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Martin Neitzel, Jennifer Marugg
  • N-Substituted Benzene Sulfonamides
    Publication number: 20110212920
    Abstract: Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. In Formula (I), R1, R2, R3, R4, R3?, R10 and R11 are as described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).
    Type: Application
    Filed: May 9, 2011
    Publication date: September 1, 2011
    Inventors: Martin Neitzel, Michael S. Dappen, Jennifer Marugg
  • N-substituted benzene sulfonamides
    Patent number: 7939657
    Abstract: Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. In Formula (I), R1, R2, R3, R4, R3?, R10 and R11 are as described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).
    Type: Grant
    Filed: April 23, 2007
    Date of Patent: May 10, 2011
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Martin Neitzel, Michael S. Dappen, Jennifer Marugg
  • Substituted pyrazole derivatives and related compounds as bradykinin Breceptor antagonists
    Patent number: 7432379
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: October 7, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Jay S. Tung, Albert W. Garofalo, Michael A. Pleiss, Jing Wu, David W. G. Wone, Ashley C. Guinn, Darren B. Dressen, R. Jeffrey Neitz, Jennifer Marugg, Martin Neitzel
  • 4-bromo-5-(2-chloro-benzoylamino)-1H-pyrazole-3-carboxylic acid amide derivatives and related compounds as bradykinin Breceptor antagonists for the treatment of inflammatory diseases
    Patent number: 7417152
    Abstract: Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: August 26, 2008
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Jay S. Tung, Albert W. Garofalo, Michael A. Pleiss, Jing Wu, David W. G. Wone, Ashley C. Guinn, Darren B. Dressen, R. Jeffrey Neitz, Jennifer Marugg, Martin Neitzel
  • N-Substituted Benzene Sulfonamides
    Publication number: 20070191341
    Abstract: Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. In Formula (I), R1, R2, R3, R4, R3?, R10 and R11 are as described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).
    Type: Application
    Filed: April 23, 2007
    Publication date: August 16, 2007
    Inventors: Martin Neitzel, Michael Dappen, Jennifer Marugg
  • 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (1-aminocarbonyl)eth-1-yl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
    Publication number: 20070161633
    Abstract: Disclosed are compounds of formulae (I) and (II) that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action. Wherein Z is selected from O, S and NH; Q of formula (III) and the other substituents are as defined in claim 1.
    Type: Application
    Filed: April 30, 2004
    Publication date: July 12, 2007
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Jay Tung, Albert Garofalo, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, Jennifer Marugg, Martin Neitzel
  • 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carboxylic acid (phenyl) amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
    Publication number: 20070123531
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Application
    Filed: April 30, 2004
    Publication date: May 31, 2007
    Inventors: Albert Garofalo, Jay Tung, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, Jennifer Marugg, Martin Neitzel
  • N-substituted benzene sulfonamides
    Patent number: 7208488
    Abstract: Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. In Formula (I), R1, R2, R3, R4, R3?, R10 and R11 are as described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: April 24, 2007
    Assignee: Elan Pharmaceuticals, Inc.
    Inventors: Martin Neitzel, Michael S. Dappen, Jennifer Marugg
  • 4-Bromo-5-(2-chloro-benzoylamino)-1h-pyrazole-3-carvoxylic acid amide derivatives and related compounds as bradykinin b1 receptor antagonists for the treatment of inflammatory diseases
    Publication number: 20060281733
    Abstract: Disclosed are compounds of formula I and II that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Application
    Filed: April 30, 2004
    Publication date: December 14, 2006
    Inventors: Jay Tung, Albert Garofalo, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, R. Jeffrey Neitz, Jennifer Marugg, Martin Neitzel
  • N-cyclic sulfonamido inhibitors of gamma secretase
    Publication number: 20060035884
    Abstract: The invention provides N-cyclic sulfonamido compounds for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula I, wherein R4, R5, R6, R7, and R8, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula I as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula I.
    Type: Application
    Filed: May 20, 2005
    Publication date: February 16, 2006
    Applicant: Elan Pharmaceuticals, Inc.
    Inventors: Martin Neitzel, Jennifer Marugg
  • N-substituted benzene sulfonamides
    Publication number: 20050245573
    Abstract: The invention provides N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. Compounds of particular interest are defined by Formula (I), wherein R1, R2, R3, R4, and R3?, are as described in the specification. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders, including Alzheimer's disease using compounds of Formula (I).
    Type: Application
    Filed: March 11, 2005
    Publication date: November 3, 2005
    Inventors: Martin Neitzel, Jennifer Marugg
  • N-substituted benzene sulfonamides
    Publication number: 20050165003
    Abstract: Disclosed are N-substituted benzenesulfonamides for use in treating or preventing cognitive disorders, such as Alzheimer's Disease. In Formula (I), R1, R2, R3, R4, R3?, R10 and R11 are as described herein. The invention also encompasses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of treating cognitive disorders using compounds of Formula (I).
    Type: Application
    Filed: October 29, 2004
    Publication date: July 28, 2005
    Inventors: Martin Neitzel, Michael Dappen, Jennifer Marugg
  • Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
    Publication number: 20050038099
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Application
    Filed: April 30, 2004
    Publication date: February 17, 2005
    Inventors: Jay Tung, Albert Garofalo, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, Jennifer Marugg, Martin Neitzel
  • Selected substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
    Publication number: 20050032868
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Application
    Filed: April 30, 2004
    Publication date: February 10, 2005
    Inventors: Albert Garofalo, Jay Tung, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, Jennifer Marugg, Martin Neitzel
  • Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
    Publication number: 20050020659
    Abstract: Disclosed are compounds that are bradykinin B1 receptor antagonists and are useful for treating diseases, or relieving adverse symptoms associated with disease conditions, in mammals mediated by bradykinin B1 receptor. Certain of the compounds exhibit increased potency and are also expected to exhibit increased duration of action.
    Type: Application
    Filed: April 30, 2004
    Publication date: January 27, 2005
    Inventors: Jay Tung, Albert Garofalo, Michael Pleiss, Jing Wu, David Wone, Ashley Guinn, Darren Dressen, R. Neitz, Jennifer Marugg, Martin Neitzel